In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Pfizer (PFE – Research Report), with a ...

Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy ...

Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year ...

We like to see robust dividend yields, but that doesn't matter if the payment isn't sustainable. Based on the last payment, the company wasn't making enough to cover what it was paying to ...

Pfizer (PFE) reachead $26.91 at the closing of the latest trading ... Nonspecialist investors have shifted their focus to other sectors, such as tech, following the outcome of the election and ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other healthcare stocks Jim Cramer has made bold predictions about. Healthcare has been one of Jim ...

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00. The company’s shares closed yesterday at $25.23. Pick the ...

Use a stop loss below $24 to manage risk, as PFE's current position offers a higher reward-to-risk ratio within the consolidation phase. Looking at Chart 1 above, you can see the blue arrow in ...